ALK and non-small cell lung carcinoma: TKIs directed against EGFR, ALK, VEGF, and KRAS [34,35,49,50,51] have shown significant clinical benefits in molecularly stratified NSCLC subtypes [52], yet therapeutic resistance and tumor recurrence continue to impede long-term survival.